**Supplemental Table 1. Baseline sociodemographic and clinical characteristics of medulloblastoma patients in the NOA-07 study who underwent neurocognitive testing at the 18-month assessment**

|  |  |
| --- | --- |
|  | **Baseline characteristics****(n=7)** |
| Age in years at diagnosis Mean (SD; range) | 37 (6; 27-43) |
| Gender, no. (%) Male Female | 4 (57%)3 (43%) |
| KPS, median (range) | 90 (70-100) |
| Histopathological entity, no. (%) Classic Desmoplastic/nodular Other | 3 (43%)3 (43%)1 (14%) |
| Molecular entity, no. (%) SHH-driven, p53wt SHH-driven, p53mut WNT-driven Group 3 Group 4 Not availableRadiochemotherapy completed | 5 (71.4%)0001 (14.3%)1 (14.3%)7 (100%) |
| Adjuvant chemotherapy received | 7 (100%) |
| Chemotherapy cycles, median (range) | 8 (6-8) |
| Disease progression, no. (%) | 2 (29%) |
| Progression-free survival in years, median (range); (n=5) | 3.2 (1.8-4.5) |
| 5-year overall survival rate (%) | 5 (71.4%) |

*SD, standard deviation; KPS, Karnofsky Performance Status*